Director Kimberly Manhard filed an amended Form 4/A with the SEC on September 18, 2026, restating a June 4, 2026 original filing to correct the number of stock options granted due to an administrative error.

Key Highlights

  • Reporting person: Kimberly Manhard, Director at Inhibrx Biosciences, Inc. (NASDAQ:INBX)
  • Transaction: Acquisition (Code A) of a stock option (right to buy) covering 10,000 shares of Common Stock, dated June 3, 2026
  • Exercise price: $95.22 per share
  • Vesting: The option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through that date
  • Expiration: June 3, 2036
  • Price paid: $0 for the derivative security
  • Amendment reason: The filing states the amendment corrects "the number of options granted to the Reporting Person due to an administrative error"

Manhard Option Grant Restated After Administrative Error in Original Filing

According to the amended filing, Kimberly Manhard, a Director at Inhibrx Biosciences, Inc., received a stock option grant on June 3, 2026, covering 10,000 shares of Common Stock at an exercise price of $95.22 per share. The option was acquired at a price of $0 and is held directly. Following the reported transaction, Manhard beneficially owns 10,000 derivative securities (the option shares) on a direct basis.

The Form 4/A, signed on September 18, 2026 by Kelly D. Deck as attorney-in-fact for Kimberly Manhard, states that it "restates the original Form 4 filed on June 4, 2026 in its entirety to correct the number of options granted to the Reporting Person due to an administrative error." The filing does not specify what the originally reported option count was before the correction. No non-derivative securities were reported as acquired or disposed of in connection with this transaction.

The option will become fully exercisable on June 3, 2027, contingent on the reporting person's continued service through that date, and will expire on June 3, 2036, according to the filing's explanation of responses. No Table I non-derivative activity was recorded.

What Was Disclosed

Inhibrx Biosciences Director Kimberly Manhard amended a prior Form 4 to correct an option grant quantity. The restated filing reports an acquisition of a stock option for 10,000 shares of Common Stock at $95.22, granted June 3, 2026, with a single cliff-vest date of June 3, 2027.